Join Mergr to view all 275 acquisitions of life science companies in 2016, including 25 acquisitions by private equity firms, and 250 by strategics.
AstraZeneca - Small Molecule Anti-Infective Business includes the commercialization and development rights to the newly approved EU drug Zavicefta™ (ceftazidime-avibactam), the marketed agents Merrem™/Meronem™ (meropenem) and Zinforo™ (ceftaroline fosamil), and the clinical development assets aztreonam-avibactam (ATM-AVI) and CXL.
AstraZeneca - Small Molecule Anti-Infective Business was acquired by Pfizer on August 24, 2016.
Join Mergr to view this profile - and discover more life science acquisitions of companies like AstraZeneca - Small Molecule Anti-Infective Business.
We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.
Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.
Try us for 1 week free today!
No obligation. Cancel anytime.